Lung Cancer News
Squamous cell lung cancers, a form of NSCLC, are glucose-dependent, while adenocarcinoma NSCLC tumors are largely glucose-independent.
Researchers call for additional clinical trials investigating radiotherapy followed by immune checkpoint blockade for patients with NSCLC.
Neoadjuvant nivolumab is safe and provides a comparable pathologic response to that with cisplatin-based neoadjuvant chemotherapy in resectable non-small cell lung cancer.
The prognostic marker, which was evaluated among patients with stage III NSCLC, held after adjusting for variables including chemoradiation approach and performance status.
A liquid biopsy analysis shows inter- and intra-patient heterogeneity of EGFR resistance mutations among patients with lung adenocarcinoma who received EGFR-directed TKI therapy.
The US Affordable Care Act may have increased the proportion of patients with cancer diagnosed at stage I, according to a study.
Adjuvant gefitinib significantly prolongs disease-free survival compared with vinorelbine plus cisplatin among patients with stage II to III non-small cell lung cancer.
An interim analysis of the PACIFIC trial found that PFS was significantly prolonged compared with placebo.
Alectinib prolongs progression-free survival with less toxicity compared with crizotinib among Japanese patients with ALK-positive non-small cell lung cancer.
The FDA approved pembrolizumab in combination with pemetrexed and carboplatin as a first-line treatment for metastatic lung cancer.
Biomarker-driven treatment of non-small cell lung cancer with celecoxib failed to improve outcomes.
This anti-CD27 antibody demonstrated clinical activity among and was well-tolerated by patients with solid tumors including melanoma, prostate cancer, and renal cell carcinoma.
Safety, tolerability, and efficacy of palbociclib in combination with cisplatin or carboplatin among patients with advanced/metastatic solid tumors.
The FDA has approved brigatinib, a dual ALK and EGFR inhibitor, for the treatment of patients with ALK-positive NSCLC who progressed while receiving or are intolerant to crizotinib.
Chromosome instability was associated with an increased risk of recurrence and mortality among patients with early-stage NSCLC.
Timing might affect the results of an EGFR mutation-frequency circulating tumor DNA (ctDNA) test among patients with advanced NSCLC.
Researchers are evaluating whether hypoIGRT is an effective treatment strategy for patients with stage I NSCLC who are not candidates for surgery.
Researchers are attempting to determine whether SPECT/CT imaging is non-inferior to PET/CT imaging for lung cancer.
Patients who reported better clinician communication or an improved satisfaction with their treatment were more likely to be adherent.
Immune checkpoint inhibition with nivolumab is associated with durable clinical responses and a 16% 5-year survival rate among heavily pretreated patients with advanced NSCLC.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|